1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Myeloproliferative Disorders - Pipeline Review, H2 2013

Myeloproliferative Disorders - Pipeline Review, H2 2013

  • December 2013
  • -
  • Global Markets Direct
  • -
  • 87 pages

Myeloproliferative Disorders - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Myeloproliferative Disorders - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Myeloproliferative Disorders, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Myeloproliferative Disorders. Myeloproliferative Disorders - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Myeloproliferative Disorders.
- A review of the Myeloproliferative Disorders products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Myeloproliferative Disorders pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Myeloproliferative Disorders.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Myeloproliferative Disorders pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Myeloproliferative Disorders - Pipeline Review, H2 2013
Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Myeloproliferative Disorders Overview 8
Therapeutics Development 9
Pipeline Products for Myeloproliferative Disorders - Overview 9
Pipeline Products for Myeloproliferative Disorders - Comparative Analysis 10
Myeloproliferative Disorders - Therapeutics under Development by Companies 11
Myeloproliferative Disorders - Therapeutics under Investigation by Universities/Institutes 13
Myeloproliferative Disorders - Pipeline Products Glance 14
Clinical Stage Products 14
Early Stage Products 15
Myeloproliferative Disorders - Products under Development by Companies 16
Myeloproliferative Disorders - Products under Investigation by Universities/Institutes 17
Myeloproliferative Disorders - Companies Involved in Therapeutics Development 18
Eli Lilly and Company 18
Genentech, Inc. 19
Merck and Co., Inc. 20
Nanotherapeutics, Inc. 21
Synta Pharmaceuticals Corp. 22
Italfarmaco S.p.A. 23
Celon Pharma Sp. z o.o. 24
Agios Pharmaceuticals, Inc. 25
Onconova Therapeutics, Inc. 26
KaloBios Pharmaceuticals, Inc. 27
EpiZyme, Inc. 28
Myeloproliferative Disorders - Therapeutics Assessment 29
Assessment by Monotherapy Products 29
Assessment by Target 30
Assessment by Mechanism of Action 33
Assessment by Route of Administration 36
Assessment by Molecule Type 38
Assessment by Therapeutic Class 40
Drug Profiles 43
Triapine - Drug Profile 43
Product Description 43
Mechanism of Action 43
RandD Progress 43
givinostat - Drug Profile 45
Product Description 45
Mechanism of Action 45
RandD Progress 45
ganetespib - Drug Profile 47
Product Description 47
Mechanism of Action 47
RandD Progress 47
KB-004 - Drug Profile 51
Product Description 51
Mechanism of Action 51
RandD Progress 51
gandotinib - Drug Profile 53
Product Description 53
Mechanism of Action 53
RandD Progress 53
EPZ-5676 - Drug Profile 55
Product Description 55
Mechanism of Action 55
RandD Progress 55
ON-044580 - Drug Profile 56
Product Description 56
Mechanism of Action 56
RandD Progress 56
Small Molecules To Inhibit JAK2 For Myeloproliferative Neoplasms - Drug Profile 57
Product Description 57
Mechanism of Action 57
RandD Progress 57
Kinase Inhibitors for Oncology - Drug Profile 58
Product Description 58
Mechanism of Action 58
RandD Progress 58
Small Molecule To Inhibit JAK2 For Myeloproliferative Disorder - Drug Profile 59
Product Description 59
Mechanism of Action 59
RandD Progress 59
AG-120 - Drug Profile 60
Product Description 60
Mechanism of Action 60
RandD Progress 60
CPL-407-22 - Drug Profile 62
Product Description 62
Mechanism of Action 62
RandD Progress 62
Jak2 Inhibitors - Drug Profile 63
Product Description 63
Mechanism of Action 63
RandD Progress 63
Myeloproliferative Disorders - Recent Pipeline Updates 64
Myeloproliferative Disorders - Dormant Projects 77
Myeloproliferative Disorders - Product Development Milestones 78
Featured News and Press Releases 78
Apr 01, 2013: Indian Supreme Court Denies Patent For Novartis's Updated Version Of Leukemia Drug Glivec 78
Dec 10, 2012: Onconova Presents Positive Clinical Results Of Rigosertib At ASH Meeting 78
Dec 12, 2011: Lilly Oncology Reveals Findings From Study Of JAK2 Inhibitor For Blood Cancers At ASH Meeting 80
Dec 06, 2010: Longer-term Phase III data show Novartis drug Tasigna continues to surpass Glivec in slowing disease progression in patients with newly diagnosed CML 81
Sep 03, 2010: Celgene Officially Notified Of ANDA Filing For REVLIMID 82
Aug 02, 2010: miRagen Announces Publication Of Data On microRNA-451 In Journal Genes and Development 83
Jun 04, 2010: New data at ASCO show Novartis drug Tasigna surpasses Glivec in slowing disease progression for newly diagnosed CML patients 83
Feb 11, 2010: YM BioSciences Provides Updates On CYT387 84
Dec 08, 2009: Novartis Tasigna trial shows superior results to Glivec in patients with early-stage chronic myeloid leukemia 84
Dec 07, 2009: Incyte Corporation Announces Three Phase II Trials Results Of INCB18424 At 51st American Society Of Hematology Annual Meeting 85
Appendix 86
Methodology 86
Coverage 86
Secondary Research 86
Primary Research 86
Expert Panel Validation 86
Contact Us 87
Disclaimer 87



List of Tables

Number of Products under Development for Myeloproliferative Disorders, H2 2013 9
Number of Products under Development for Myeloproliferative Disorders - Comparative Analysis, H2 2013 10
Number of Products under Development by Companies, H2 2013 12
Number of Products under Investigation by Universities/Institutes, H2 2013 13
Comparative Analysis by Clinical Stage Development, H2 2013 14
Comparative Analysis by Early Stage Development, H2 2013 15
Products under Development by Companies, H2 2013 16
Products under Investigation by Universities/Institutes, H2 2013 17
Myeloproliferative Disorders - Pipeline by Eli Lilly and Company, H2 2013 18
Myeloproliferative Disorders - Pipeline by Genentech, Inc., H2 2013 19
Myeloproliferative Disorders - Pipeline by Merck and Co., Inc., H2 2013 20
Myeloproliferative Disorders - Pipeline by Nanotherapeutics, Inc., H2 2013 21
Myeloproliferative Disorders - Pipeline by Synta Pharmaceuticals Corp., H2 2013 22
Myeloproliferative Disorders - Pipeline by Italfarmaco S.p.A., H2 2013 23
Myeloproliferative Disorders - Pipeline by Celon Pharma Sp. z o.o., H2 2013 24
Myeloproliferative Disorders - Pipeline by Agios Pharmaceuticals, Inc., H2 2013 25
Myeloproliferative Disorders - Pipeline by Onconova Therapeutics, Inc., H2 2013 26
Myeloproliferative Disorders - Pipeline by KaloBios Pharmaceuticals, Inc., H2 2013 27
Myeloproliferative Disorders - Pipeline by EpiZyme, Inc., H2 2013 28
Assessment by Monotherapy Products, H2 2013 29
Number of Products by Stage and Target, H2 2013 32
Number of Products by Stage and Mechanism of Action, H2 2013 35
Number of Products by Stage and Route of Administration, H2 2013 37
Number of Products by Stage and Molecule Type, H2 2013 39
Number of Products by Stage and Therapeutic Class, H2 2013 42
Myeloproliferative Disorders Therapeutics - Recent Pipeline Updates, H2 2013 64
Myeloproliferative Disorders - Dormant Projects, H2 2013 77



List of Figures

Number of Products under Development for Myeloproliferative Disorders, H2 2013 9
Number of Products under Development for Myeloproliferative Disorders - Comparative Analysis, H2 2013 10
Number of Products under Development by Companies, H2 2013 11
Number of Products under Investigation by Universities/Institutes, H2 2013 13
Comparative Analysis by Clinical Stage Development, H2 2013 14
Comparative Analysis by Early Stage Products, H2 2013 15
Assessment by Monotherapy Products, H2 2013 29
Number of Products by Top 10 Target, H2 2013 30
Number of Products by Stage and Top 10 Target, H2 2013 31
Number of Products by Top 10 Mechanism of Action, H2 2013 33
Number of Products by Stage and Top 10 Mechanism of Action, H2 2013 34
Number of Products by Top 10 Route of Administration, H2 2013 36
Number of Products by Stage and Top 10 Route of Administration, H2 2013 37
Number of Products by Top 10 Molecule Type, H2 2013 38
Number of Products by Stage and Top 10 Molecule Type, H2 2013 39
Number of Products by Top 10 Therapeutic Class, H2 2013 40
Number of Products by Stage and Top 10 Therapeutic Class, H2 2013 41



Companies Mentioned

Eli Lilly and Company
Genentech, Inc.
Merck and Co., Inc.
Nanotherapeutics, Inc.
Synta Pharmaceuticals Corp.
Italfarmaco S.p.A.
Celon Pharma Sp. z o.o.
Agios Pharmaceuticals, Inc.
Onconova Therapeutics, Inc.
KaloBios Pharmaceuticals, Inc.
EpiZyme, Inc.

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Tyrosine Protein Kinase Me ...

Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) - Pipeline Review, H2 2016

Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Histone ...

Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) - Pipeline Review, H2 2016

Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) - Pipeline Review, H2 2016 Summary Global ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.